These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
478 related articles for article (PubMed ID: 12809514)
61. Dilysine retrieval signal-containing p24 proteins collaborate in inhibiting γ-cleavage of amyloid precursor protein. Hasegawa H; Liu L; Nishimura M J Neurochem; 2010 Nov; 115(3):771-81. PubMed ID: 20807314 [TBL] [Abstract][Full Text] [Related]
62. JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo. Petit A; Pasini A; Alves Da Costa C; Ayral E; Hernandez JF; Dumanchin-Njock C; Phiel CJ; Marambaud P; Wilk S; Farzan M; Fulcrand P; Martinez J; Andrau D; Checler F J Neurosci Res; 2003 Nov; 74(3):370-7. PubMed ID: 14598313 [TBL] [Abstract][Full Text] [Related]
63. Recent advances in the development of gamma-secretase inhibitors. Josien H Curr Opin Drug Discov Devel; 2002 Jul; 5(4):513-25. PubMed ID: 12197309 [TBL] [Abstract][Full Text] [Related]
64. gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Sisodia SS; St George-Hyslop PH Nat Rev Neurosci; 2002 Apr; 3(4):281-90. PubMed ID: 11967558 [No Abstract] [Full Text] [Related]
65. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Paris D; Quadros A; Patel N; DelleDonne A; Humphrey J; Mullan M Eur J Pharmacol; 2005 May; 514(1):1-15. PubMed ID: 15878319 [TBL] [Abstract][Full Text] [Related]
66. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Moehlmann T; Winkler E; Xia X; Edbauer D; Murrell J; Capell A; Kaether C; Zheng H; Ghetti B; Haass C; Steiner H Proc Natl Acad Sci U S A; 2002 Jun; 99(12):8025-30. PubMed ID: 12048239 [TBL] [Abstract][Full Text] [Related]
67. A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Amtul Z; Lewis PA; Piper S; Crook R; Baker M; Findlay K; Singleton A; Hogg M; Younkin L; Younkin SG; Hardy J; Hutton M; Boeve BF; Tang-Wai D; Golde TE Neurobiol Dis; 2002 Mar; 9(2):269-73. PubMed ID: 11895378 [TBL] [Abstract][Full Text] [Related]
68. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. Sastre M; Steiner H; Fuchs K; Capell A; Multhaup G; Condron MM; Teplow DB; Haass C EMBO Rep; 2001 Sep; 2(9):835-41. PubMed ID: 11520861 [TBL] [Abstract][Full Text] [Related]
69. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. Bakshi P; Jin C; Broutin P; Berhane B; Reed J; Mullan M Bioorg Med Chem; 2009 Dec; 17(23):8102-12. PubMed ID: 19853461 [TBL] [Abstract][Full Text] [Related]
70. Enhanced delivery of gamma-secretase inhibitor DAPT into the brain via an ascorbic acid mediated strategy. Quéléver G; Kachidian P; Melon C; Garino C; Laras Y; Pietrancosta N; Sheha M; Louis Kraus J Org Biomol Chem; 2005 Jul; 3(13):2450-7. PubMed ID: 15976862 [TBL] [Abstract][Full Text] [Related]
71. Destruxin E decreases Beta-amyloid generation by reducing colocalization of beta-amyloid-cleaving enzyme 1 and beta-amyloid protein precursor. Itoh N; Okochi M; Tagami S; Nishitomi K; Nakayama T; Yanagida K; Fukumori A; Jiang J; Mori K; Hosono M; Kikuchi J; Nakano Y; Takinami Y; Dohi K; Nishigaki A; Takemoto H; Minagawa K; Katoh T; Willem M; Haass C; Morihara T; Tanaka T; Kudo T; Hasegawa H; Nishimura M; Sakaguchi G; Kato A; Takeda M Neurodegener Dis; 2009; 6(5-6):230-9. PubMed ID: 19738368 [TBL] [Abstract][Full Text] [Related]
72. Role of Notch-1 intracellular domain in activation of rheumatoid synoviocytes. Nakazawa M; Ishii H; Aono H; Takai M; Honda T; Aratani S; Fukamizu A; Nakamura H; Yoshino S; Kobata T; Nishioka K; Nakajima T Arthritis Rheum; 2001 Jul; 44(7):1545-54. PubMed ID: 11465706 [TBL] [Abstract][Full Text] [Related]
73. Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia. Wang R; Zhang YW; Zhang X; Liu R; Zhang X; Hong S; Xia K; Xia J; Zhang Z; Xu H FASEB J; 2006 Jun; 20(8):1275-7. PubMed ID: 16645044 [TBL] [Abstract][Full Text] [Related]
74. gamma-Secretase inhibitors as molecular probes of presenilin function. Wolfe MS J Mol Neurosci; 2001 Oct; 17(2):199-204. PubMed ID: 11816793 [TBL] [Abstract][Full Text] [Related]
75. A portrait of Alzheimer secretases--new features and familiar faces. Esler WP; Wolfe MS Science; 2001 Aug; 293(5534):1449-54. PubMed ID: 11520976 [TBL] [Abstract][Full Text] [Related]
76. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. Liao YF; Wang BJ; Cheng HT; Kuo LH; Wolfe MS J Biol Chem; 2004 Nov; 279(47):49523-32. PubMed ID: 15347683 [TBL] [Abstract][Full Text] [Related]
77. Presenilin 1 mutations activate gamma 42-secretase but reciprocally inhibit epsilon-secretase cleavage of amyloid precursor protein (APP) and S3-cleavage of notch. Chen F; Gu Y; Hasegawa H; Ruan X; Arawaka S; Fraser P; Westaway D; Mount H; St George-Hyslop P J Biol Chem; 2002 Sep; 277(39):36521-6. PubMed ID: 12119298 [TBL] [Abstract][Full Text] [Related]
78. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Lichtenthaler SF; Beher D; Grimm HS; Wang R; Shearman MS; Masters CL; Beyreuther K Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1365-70. PubMed ID: 11805291 [TBL] [Abstract][Full Text] [Related]
79. Identification of two novel synaptic γ-secretase associated proteins that affect amyloid β-peptide levels without altering Notch processing. Frykman S; Teranishi Y; Hur JY; Sandebring A; Yamamoto NG; Ancarcrona M; Nishimura T; Winblad B; Bogdanovic N; Schedin-Weiss S; Kihara T; Tjernberg LO Neurochem Int; 2012 Jul; 61(1):108-18. PubMed ID: 22521230 [TBL] [Abstract][Full Text] [Related]
80. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. Evin G; Sernee MF; Masters CL CNS Drugs; 2006; 20(5):351-72. PubMed ID: 16696577 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]